BSE Live
Feb 24, 09:49Prev. Close
874.05
Open Price
873.15
Bid Price (Qty.)
864.95 (29)
Offer Price (Qty.)
866.50 (22)
NSE Live
Feb 24, 09:49Prev. Close
874.75
Open Price
870.00
Bid Price (Qty.)
865.30 (32)
Offer Price (Qty.)
865.70 (2)
| Key Financial Ratios of Strides Pharma Science (in Rs. Cr.) | Dec 04 | |
| Per Share Ratios | ||
| Basic EPS (Rs.) | 13.03 | |
| Diluted EPS (Rs.) | 13.03 | |
| Cash EPS (Rs.) | 18.70 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 64.13 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 64.13 | |
| Revenue from Operations/Share (Rs.) | 132.77 | |
| PBDIT/Share (Rs.) | 29.43 | |
| PBIT/Share (Rs.) | 24.14 | |
| PBT/Share (Rs.) | 16.02 | |
| Net Profit/Share (Rs.) | 12.35 | |
| NP After MI And SOA / Share (Rs.) | 13.03 | |
| Profitability Ratios | ||
| PBDIT Margin (%) | 22.16 | |
| PBIT Margin (%) | 18.17 | |
| PBT Margin (%) | 12.06 | |
| Net Profit Margin (%) | 9.30 | |
| NP After MI And SOA Margin (%) | 9.81 | |
| Return on Networth/Equity (%) | 21.18 | |
| Return on Capital Employed (%) | 11.28 | |
| Return on Assets (%) | 8.04 | |
| Total Debt/Equity (X) | 1.05 | |
| Asset Turnover Ratio (%) | 81.98 | |
| Liquidity Ratios | ||
| Current Ratio (X) | 1.64 | |
| Quick Ratio (X) | 1.33 | |
| Inventory Turnover Ratio (X) | 9.17 | |
| Dividend Payout Ratio (NP) (%) | 11.50 | |
| Dividend Payout Ratio (CP) (%) | 7.74 | |
| Earnings Retention Ratio (%) | 88.50 | |
| Cash Earnings Retention Ratio (%) | 92.26 | |
| Coverage Ratios | ||
| Interest Coverage Ratios (%) | 2.98 | |
| Interest Coverage Ratios (Post Tax) (%) | 2.98 | |
| Valuation Ratios | ||
| Enterprise Value (Cr.) | 922.31 | |
| EV/Net Operating Revenue (X) | 2.06 | |
| EV/EBITDA (X) | 9.28 | |
| MarketCap/Net Operating Revenue (X) | 1.60 | |
| Retention Ratios (%) | 88.49 | |
| Price/BV (X) | 3.46 | |
| Price/Net Operating Revenue | 1.60 | |
| Earnings Yield | 0.06 |
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
26.12.2025
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
03.02.2026
Strides Pharma Consolidated December 2025 Net Sales at Rs 1,194.65 crore, up 3.55% Y-o-Y
03.02.2026
Strides Pharma Standalone December 2025 Net Sales at Rs 553.63 crore, up 0.49% Y-o-Y
10.11.2025
Strides Pharma Standalone September 2025 Net Sales at Rs 522.15 crore, down 14.4% Y-o-Y
31.10.2025
Strides Pharma Consolidated September 2025 Net Sales at Rs 1,220.83 crore, up 1.64% Y-o-Y
12.04.2021
Strides Pharma Science Q4 PAT may dip 488.7% YoY to Rs. 72.3 cr: Sharekhan
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
18.01.2018
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
17.08.2016